Helus Pharma (HELP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Sep, 2026Opening remarks and agenda
Meeting commenced with introductions of directors and officers, and explanation of the virtual platform for voting and Q&A.
Proof of notice and quorum confirmed, with agenda items outlined for shareholder reference.
Corporate governance
Voting procedures explained, with each share entitled to one vote per resolution.
Scrutineer tabulated votes prior to the cutoff, and results to be available after the meeting.
Financial performance review
Financial statements for the year ended March 31, 2026, and auditor's report presented and made available online.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Helus Pharma
- Lead candidate HLP003 nears phase III readout for adjunctive MDD, with NDA filing targeted for 2028.HELP
H.C. Wainwright 28th Annual Global Investment Conference - Phase III data for deuterated psilocin in adjunctive MDD expected Q4 2026, targeting superior safety and efficacy.HELP
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - CYB-003 phase III readout expected Q4, with NDA filing and commercialization prep underway.HELP
12th Annual Cantor Fitzgerald Global Healthcare Conference - Phase III data for adjunctive MDD expected in Q4, with strong efficacy and high industry anticipation.HELP
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III data for a differentiated adjunctive depression therapy is expected in Q4.HELP
Canaccord Genuity's 46th Annual Growth Conference - Advanced late-stage clinical programs and strengthened cash reserves, despite higher net loss.HELP
Q1 2027 - FDA guidance and trial rigor shape psychedelic therapy development as key programs advance toward pivotal data.HELP
TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024 - Net loss widened to $148M on higher R&D, but cash rose to $157M after major financings.HELP
Q4 2026 - 100% response and 71% remission at 12 months for 16mg; Phase 3 trials underway.HELP
Status Update